Dechra Pharmaceuticals Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Dechra Pharmaceuticals ha aumentado sus beneficios a una tasa media anual de 1.1%, mientras que los beneficios de la industria de Pharmaceuticals han experimentado un descenso anual de 5.2%. Los ingresos han ido creciendo a una tasa media de 12.2% al año.
Información clave
1.1%
Tasa de crecimiento de los beneficios
-0.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Pharmaceuticals | 14.1% |
| Tasa de crecimiento de los ingresos | 12.2% |
| Rentabilidad financiera | -3.7% |
| Margen neto | -3.7% |
| Última actualización de beneficios | 30 Jun 2023 |
Actualizaciones de resultados anteriores recientes
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31
A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17
Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Desglose de ingresos y gastos
Cómo gana y gasta dinero Dechra Pharmaceuticals. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 23 | 762 | -28 | 352 | 61 |
| 31 Mar 23 | 744 | 6 | 316 | 55 |
| 31 Dec 22 | 727 | 40 | 280 | 49 |
| 30 Sep 22 | 704 | 49 | 267 | 43 |
| 30 Jun 22 | 682 | 58 | 253 | 36 |
| 31 Mar 22 | 661 | 66 | 239 | 35 |
| 31 Dec 21 | 641 | 73 | 225 | 35 |
| 30 Sep 21 | 624 | 64 | 224 | 36 |
| 30 Jun 21 | 608 | 56 | 222 | 37 |
| 31 Mar 21 | 587 | 50 | 215 | 36 |
| 31 Dec 20 | 566 | 44 | 208 | 35 |
| 30 Sep 20 | 541 | 39 | 203 | 35 |
| 30 Jun 20 | 515 | 34 | 199 | 34 |
| 31 Mar 20 | 507 | 31 | 200 | 34 |
| 31 Dec 19 | 499 | 29 | 201 | 33 |
| 30 Sep 19 | 490 | 30 | 198 | 32 |
| 30 Jun 19 | 482 | 31 | 196 | 32 |
| 31 Mar 19 | 463 | 28 | 191 | 31 |
| 31 Dec 18 | 444 | 25 | 186 | 29 |
| 30 Sep 18 | 426 | 30 | 171 | 28 |
| 30 Jun 18 | 407 | 36 | 156 | 26 |
| 31 Mar 18 | 394 | 40 | 147 | 26 |
| 31 Dec 17 | 381 | 43 | 137 | 26 |
| 30 Sep 17 | 370 | 35 | 133 | 26 |
| 30 Jun 17 | 359 | 26 | 129 | 26 |
| 31 Mar 17 | 334 | 19 | 122 | 23 |
| 31 Dec 16 | 309 | 11 | 115 | 19 |
| 30 Sep 16 | 278 | 12 | 105 | 15 |
| 30 Jun 16 | 248 | 13 | 95 | 10 |
| 31 Mar 16 | 230 | 17 | 90 | 10 |
| 31 Dec 15 | 213 | 20 | 84 | 9 |
| 30 Sep 15 | 208 | 20 | 82 | 9 |
| 30 Jun 15 | 203 | 19 | 81 | 9 |
| 31 Mar 15 | 201 | 21 | 79 | 8 |
| 31 Dec 14 | 199 | 22 | 77 | 8 |
| 30 Sep 14 | 196 | 21 | 75 | 8 |
| 30 Jun 14 | 194 | 19 | 74 | 8 |
| 31 Dec 13 | 193 | 14 | 73 | 8 |
| 30 Sep 13 | 191 | 13 | 73 | 8 |
| 30 Jun 13 | 189 | 11 | 72 | 8 |
Ingresos de calidad: DPH actualmente no es rentable.
Margen de beneficios creciente: DPH actualmente no es rentable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: DPH no es rentable, pero ha reducido pérdidas en los últimos 5 años a un ritmo de 1.1% por año.
Acelerando crecimiento: No se puede comparar el crecimiento de los beneficios de DPH en el último año con su promedio de 5 años, ya que actualmente no es rentable.
Beneficios vs. Industria: DPH no es rentable, por lo que resulta difícil comparar el crecimiento de sus beneficios en el último año con el de la industria Pharmaceuticals (10.2%).
Rentabilidad financiera
Alta ROE: DPH tiene una rentabilidad financiera negativa (-3.69%), ya que actualmente no es rentable.